2022 Dec
GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
Related Questions
New answer by Medical Oncologist at University of Texas MD Anderson Cancer Center (December 13, 2022)
Here are my top 3 presentations (specifically for breast medical oncology) that I would say are most impactful (now or soon), with slides attached.
GS3-04 - Capivas...